Thursday, August 20, 2026 Sign InRegister FREE My Account Help
Opinion
Opinion Home

Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe – Arrowhead Pharmaceuticals, Inc.

Posted by admin on Friday, April 24, 2026 at 10:46 am — No Comments | Leave a Comment

Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe  Arrowhead Pharmaceuticals, Inc.

FlameNet Weekly: the best of the forum, freshest listings, top Q&A — delivered every Sunday.
11 members · 0 new today · 0 online now · 0 posts in last 24h